In another mouse model of NASH, GLP-1 receptor agonist therapy could reduce liver steatosis and liver inflammation by reducing the influx of macrophages to the liver (Huang et al., 2010; Trevaskis et al., 2012). The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.